Search Results - "Kiladjian, J J"

Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone by Kiladjian, J-J, Giraudier, S, Cassinat, B

“…Interferon alpha (IFN-α) has been used for over 30 years to treat myeloproliferative neoplasms (MPNs). IFN-α was shown to induce clinical, hematological,…”
Get full text

The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders by Maslah, N, Cassinat, B, Verger, E, Kiladjian, J-J, Velazquez, L

“…Malignant hematological diseases are mainly because of the occurrence of molecular abnormalities leading to the deregulation of signaling pathways essential…”
Get full text

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both by Koschmieder, S, Mughal, T I, Hasselbalch, H C, Barosi, G, Valent, P, Kiladjian, J-J, Jeryczynski, G, Gisslinger, H, Jutzi, J S, Pahl, H L, Hehlmann, R, Maria Vannucchi, A, Cervantes, F, Silver, R T, Barbui, T

“…The Philadelphia-negative myeloproliferative neoplasms (MPNs) are clonal disorders involving hematopoietic stem and progenitor cells and are associated with…”
Get full text

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis by Harrison, C N, Vannucchi, A M, Kiladjian, J-J, Al-Ali, H K, Gisslinger, H, Knoops, L, Cervantes, F, Jones, M M, Sun, K, McQuitty, M, Stalbovskaya, V, Gopalakrishna, P, Barbui, T

“…Ruxolitinib is a Janus kinase (JAK) (JAK1/JAK2) inhibitor that has demonstrated superiority over placebo and best available therapy (BAT) in the Controlled…”
Get full text

Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Vannucchi, A.M., Barbui, T., Cervantes, F., Harrison, C., Kiladjian, J.-J., Kröger, N., Thiele, J., Buske, C.

Get full text

Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms by Kiladjian, J-J, Chomienne, C, Fenaux, P

“…Interferon (IFN) was the first cytokine discovered 50 years ago, with a wide range of biological properties, including immunomodulatory, proapoptotic and…”
Get full text

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis by Vannucchi, Alessandro M, Kantarjian, Hagop M, Kiladjian, Jean-Jacques, Gotlib, Jason, Cervantes, Francisco, Mesa, Ruben A, Sarlis, Nicholas J, Peng, Wei, Sandor, Victor, Gopalakrishna, Prashanth, Hmissi, Abdel, Stalbovskaya, Viktoriya, Gupta, Vikas, Harrison, Claire, Verstovsek, Srdan

“…Ruxolitinib, a potent Janus kinase 1/2 inhibitor, resulted in rapid and durable improvements in splenomegaly and disease-related symptoms in the 2 phase III…”
Get full text

Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes by KILADJIAN, J.-J, BOURGEOIS, E, LOBE, I, BRAUN, T, VISENTIN, G, BOURHIS, J.-H, FENAUX, P, CHOUAIB, S, CAIGNARD, A

“…Natural Killer (NK) cells are critical in host defense against malignant transformation and are potent antileukemic cytotoxic effectors. In the present study,…”
Get full text

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) by Barosi, G, Tefferi, A, Besses, C, Birgegard, G, Cervantes, F, Finazzi, G, Gisslinger, H, Griesshammer, M, Harrison, C, Hehlmann, R, Hermouet, S, Kiladjian, J-J, Kröger, N, Mesa, R, Mc Mullin, M F, Pardanani, A, Passamonti, F, Samuelsson, J, Vannucchi, A M, Reiter, A, Silver, R T, Verstovsek, S, Tognoni, G, Barbui, T

“…The discovery of somatic mutations, primarily JAK2 V617F and CALR , in classic BCR-ABL1 -negative myeloproliferative neoplasms (MPNs) has generated interest in…”
Get full text

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations by Marchetti, M, Barosi, G, Cervantes, F, Birgegård, G, Griesshammer, M, Harrison, C, Hehlmann, R, Kiladjian, J-J, Kröger, N, McMullin, M F, Passamonti, F, Vannucchi, A, Barbui, T

“…Ruxolitinib is an oral Janus-activated kinase 1 (JAK1)/JAK2 inhibitor approved for the treatment of patients with myelofibrosis based on the results of two…”
Get full text

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis by Passamonti, F, Giorgino, T, Mora, B, Guglielmelli, P, Rumi, E, Maffioli, M, Rambaldi, A, Caramella, M, Komrokji, R, Gotlib, J, Kiladjian, J J, Cervantes, F, Devos, T, Palandri, F, De Stefano, V, Ruggeri, M, Silver, R T, Benevolo, G, Albano, F, Caramazza, D, Merli, M, Pietra, D, Casalone, R, Rotunno, G, Barbui, T, Cazzola, M, Vannucchi, A M

“…Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms with variable risk of evolution into post-PV and post-ET…”
Get full text

Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients by Passamonti, F, Mora, B, Giorgino, T, Guglielmelli, P, Cazzola, M, Maffioli, M, Rambaldi, A, Caramella, M, Komrokji, R, Gotlib, J, Kiladjian, J J, Cervantes, F, Devos, T, Palandri, F, De Stefano, V, Ruggeri, M, Silver, R, Benevolo, G, Albano, F, Caramazza, D, Rumi, E, Merli, M, Pietra, D, Casalone, R, Barbui, T, Pieri, L, Vannucchi, A M

Get full text

Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis by Harrison, C N, Vannucchi, A M, Kiladjian, J-J, Al-Ali, H K, Gisslinger, H, Knoops, L, Cervantes, F, Jones, M M, Sun, K, McQuitty, M, Stalbovskaya, V, Gopalakrishna, P, Barbui, T

“…Correction to: Leukemia (2016) 30, 1701–1707; doi:10.1038/leu.2016.148 Following the publication of this article the authors noted that the IPSS risk…”
Get full text

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study by Jovanovic, J V, Ivey, A, Vannucchi, A M, Lippert, E, Oppliger Leibundgut, E, Cassinat, B, Pallisgaard, N, Maroc, N, Hermouet, S, Nickless, G, Guglielmelli, P, van der Reijden, B A, Jansen, J H, Alpermann, T, Schnittger, S, Bench, A, Tobal, K, Wilkins, B, Cuthill, K, McLornan, D, Yeoman, K, Akiki, S, Bryon, J, Jeffries, S, Jones, A, Percy, M J, Schwemmers, S, Gruender, A, Kelley, T W, Reading, S, Pancrazzi, A, McMullin, M F, Pahl, H L, Cross, N C P, Harrison, C N, Prchal, J T, Chomienne, C, Kiladjian, J J, Barbui, T, Grimwade, D

“…Reliable detection of JAK2 -V617F is critical for accurate diagnosis of myeloproliferative neoplasms (MPNs); in addition, sensitive mutation-specific assays…”
Get full text

What are RBC-transfusion-dependence and -independence? by Gale, R.P, Barosi, G, Barbui, T, Cervantes, F, Dohner, K, Dupriez, B, Gupta, V, Harrison, C, Hoffman, R, Kiladjian, J.-J, Mesa, R, Mc Mullin, M.F, Passamonti, F, Ribrag, V, Roboz, G, Saglio, G, Vannucchi, A, Verstovsek, S

“…Abstract The term RBC-transfusion-dependence is widely-used by hematologists to describe a condition of severe anemia typically arising when erythropoiesis is…”
Get full text

S193: GENOMIC AND FUNCTIONAL IMPACT OF TP53 INACTIVATION IN JAK2V617F MYELOPROLIFERATIVE NEOPLASMS: A TRANSGENIC MOUSE MODEL APPROACH by GOU, P., LIU, D., Lauret, E., Maslah, N., Montcuquet, V., meignin, V., Kiladjian, J.‐J., Cassinat, B., Giraudier, S.

Get full text

New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition by Chaligné, R, Tonetti, C, Besancenot, R, Roy, L, Marty, C, Mossuz, P, Kiladjian, J-J, Socié, G, Bordessoule, D, Le Bousse-Kerdilès, M-C, Vainchenker, W, Giraudier, S

“…MPL (or thrombopoietin receptor, TPO-R) 515 mutations have recently been described in 5–10% of primitive myelofibrosis (PMF) cases as decisive oncogenic events…”
Get full text

Is there consensus on consensus? by Kiladjian, J-J, Gale, R P

Get full text

P1029: MATCHING‐ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI‐0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH‐RISK MYELOFIBROSIS by Gupta, V., Mascarenhas, J., Kremyanskaya, M., Rampal, R. K., Talpaz, M., Kiladjian, J.‐J., Vannucchi, A., Verstovsek, S., Colak, G., Dey, D., Harrison, C.

Get full text

P1037: DOES EARLY INTERVENTION IN MYELOFIBROSIS IMPACT OUTCOMES? A POOLED ANALYSIS OF THE COMFORT I AND II STUDIES by Harrison, C., Kiladjian, J.‐J., Vannucchi, A. M., Mesa, R. A., Scherber, R. M., Hamer‐Maansson, J., Verstovsek, S.

Get full text